Psychedelics and Drug Interactions (Educational)

Before anything else: where Australia's law stands

Psilocybin and MDMA are Schedule 9 prohibited substances under Australia's Poisons Standard. Possession, use, or supply outside a specifically authorised framework is a criminal offence. Full stop. The one narrow exception that came into effect on 1 July 2023 allows an Authorised Prescriber , a psychiatrist who has met the TGA's approval criteria , to prescribe psilocybin (reclassified to Schedule 8 for that purpose) and MDMA (also Schedule 8) to eligible patients under that specific framework. Outside that pathway, nothing changes. The Special Access Scheme also provides a separate route for individual patient access, again with TGA oversight.

Everything discussed below is purely educational , drawn from published pharmacology literature and clinical trial reports. None of it is advice to obtain, use, or seek out any of these substances. If you're reading this hoping for a "how to," this is the wrong page.

Why drug interactions matter pharmacologically

The short version is: every drug you take affects the same biological machinery. Enzymes, receptors, transporters; they don't queue politely. When two or more substances occupy or inhibit the same pathways simultaneously, the results can be additive, antagonistic, or genuinely dangerous, and not always in predictable ways.

Classical psychedelics, psilocybin, LSD, DMT, mescaline, are primarily serotonergic. Their main mechanism involves agonism at the 5-HT2A receptor, a serotonin receptor subtype found in high density in the prefrontal cortex. That single fact has enormous downstream consequences for interactions. Any other substance that also elevates serotonin levels, or that acts on related 5-HT receptor subtypes, creates potential for additive or compounded effects. The pharmacokinetics of how these compounds are absorbed, distributed, and metabolised are equally relevant; and often the part people overlook entirely.

The serotonin system and the risk of serotonin syndrome

Serotonin syndrome is the interaction risk that dominates the clinical literature on psychedelics. It occurs when serotonergic activity in the central and peripheral nervous systems is pushed beyond a certain threshold. Symptoms described in case reports range from agitation, tremor, and hyperthermia to, in severe cases, life-threatening complications.

The interaction of particular concern in published research is between classical psychedelics and monoamine oxidase inhibitors (MAOIs). MAOIs block the enzyme that breaks down serotonin (and other monoamines including dopamine and norepinephrine), which means serotonin accumulates. Combined with a 5-HT2A agonist, the potential for overstimulation of the serotonergic system is significant. A 2016 review published in Psychopharmacology by Timmermann and colleagues examined reported adverse events and noted this as one of the highest-priority interaction concerns in clinical trial design.

SSRIs (selective serotonin reuptake inhibitors) and SNRIs present a different and somewhat more complicated picture. These medications block the serotonin transporter, increasing synaptic serotonin levels. The interaction with classical psychedelics isn't straightforwardly additive in the way MAOIs are, chronic SSRI use has actually been observed in some trial reports to blunt the subjective effects of psilocybin, possibly through 5-HT2A receptor downregulation. But this does not mean the combination is safe; the pharmacological interaction is still present, and clinical trial protocols for authorised psilocybin use typically require washout periods from SSRIs before administration, precisely because the interaction profile isn't well characterised across different SSRIs, doses, and individuals.

Lithium is another drug flagged explicitly in the psychedelic pharmacology literature. Multiple case reports describe seizure and cardiac events in people who combined lithium with classical psychedelics, LSD in particular. The mechanism isn't fully understood, but the signal in case-report data is strong enough that authorised clinical programmes universally list lithium as a contraindication.

Cannabis and cannabinoids: a specific note

I get asked about this one a lot, probably because cannabis is both more widely used and (in some forms) legally accessible in Australia via prescription. THC is psychoactive via the endocannabinoid system, primarily acting at CB1 receptors in the brain. The serotonergic and endocannabinoid systems are distinct; but not entirely separate. CB1 receptors and 5-HT2A receptors share cortical distribution and there is evidence of cross-talk at the cellular level.

In community reports and some observational studies, cannabis combined with psychedelics is described as intensifying or prolonging the psychedelic experience. The mechanism likely involves multiple pathways: THC's own psychoactive effects, its anxiogenic potential at higher doses, and possible modulation of 5-HT receptor signalling. Cannabidiol (CBD), which does not act primarily at CB1 receptors, has a distinct pharmacological profile and a lower signal for psychoactive interaction, but it is a known inhibitor of several CYP450 liver enzymes, including CYP3A4 and CYP2D6, which are involved in the metabolism of some serotonergic compounds. That's not nothing, from a pharmacokinetics standpoint.

For anyone receiving psilocybin under an Authorised Prescriber programme, concurrent cannabis use, including prescribed medicinal cannabis; would be something to disclose fully to the prescribing psychiatrist. The first-pass metabolism interactions alone warrant proper clinical consideration.

Stimulants, alcohol, and other commonly used substances

MDMA, also Schedule 8 within the Authorised Prescriber framework, otherwise Schedule 9, acts on serotonin, dopamine, and norepinephrine transporters simultaneously. Its interaction with other stimulants, including amphetamines and cocaine, raises cardiovascular risk: blood pressure and heart rate effects can compound. The interaction with alcohol is described in harm-reduction literature as masking dehydration effects, which can contribute to hyperthermia.

Alcohol's interaction with classical psychedelics like psilocybin is less well-characterised pharmacologically than the serotonin-based interactions above. Some published trial protocols simply prohibit alcohol for a set period before sessions, citing its CNS depressant effects and the potential for unpredictable modulation of the psychedelic experience, rather than a clearly defined receptor-level mechanism. I'd argue that's an honest reflection of where the evidence is; incomplete, rather than a reason to assume it's benign.

Contraindicated conditions and the "set" problem

The pharmacological interaction question can't be cleanly separated from the clinical history of the person involved. Published trial exclusion criteria consistently list personal or family history of psychosis or schizophrenia spectrum disorders as absolute contraindications for psilocybin and MDMA. This isn't purely about drug interactions in the enzymatic sense, it's about how the neuropharmacological effects of 5-HT2A agonism interact with an existing neurobiological context.

Cardiovascular conditions are a separate category. Both classical psychedelics and MDMA produce autonomic effects; changes in heart rate and blood pressure, and interactions with antihypertensives, beta-blockers, or other cardiac medications are flagged in clinical protocols as requiring individual assessment.

Last week I was working back through the Imperial College London trial papers on psilocybin, I'd set aside time after a long evening of spectacularly mediocre jazz practice; and what struck me reading the screening criteria wasn't how restrictive they were, but how granular. Each exclusion exists because someone mapped a specific pharmacological or clinical risk. That's reassuring as far as authorised research goes. It also illustrates why the idea of managing these interactions without medical oversight is, putting it plainly, not realistic.

What the Australian regulatory framework requires

Under the TGA's Authorised Prescriber pathway, the prescribing psychiatrist is responsible for assessing the full medication history of any patient, screening for contraindicated medications, and managing washout periods where required. The Schedule 8 controlled drug classification of psilocybin (within that pathway) means it is subject to state and territory controlled drug regulations as well as federal requirements, including record-keeping, prescribing quantity limits, and reporting obligations that vary by jurisdiction.

None of this framework exists outside the authorised clinical context. For substances used outside that framework, which, again, is a criminal offence; there is no clinical oversight, no interaction screening, and no safety net. The ADF (Australian Drug Foundation) notes that the unpredictability of psychedelic experiences is significantly compounded by poly-drug use and individual health factors that cannot be assessed without proper clinical history.

The pharmacology of psychedelic drug interactions is genuinely interesting science. The regulatory context in Australia is genuinely strict. Both things are true, and neither cancels the other out.

Sources

• TGA approves use of MDMA and psilocybin, Therapeutic Goods Administration (TGA)
• Psychedelics drug facts, Australian Drug Foundation (ADF)
• Pharmacology of psychedelics and drug interactions; National Center for Biotechnology Information (NCBI/NIH)
• Authorised Prescribers overview, Therapeutic Goods Administration (TGA)

, Daniel Okoro, Psychedelic science & law writer